Galena Biopharma (GALE) vs. Its Peers Critical Contrast
Galena Biopharma (NASDAQ: GALE) is one of 116 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Galena Biopharma to related companies based on the strength of its valuation, dividends, profitability, analyst recommendations, earnings, risk and institutional ownership.
Institutional & Insider Ownership
20.5% of Galena Biopharma shares are held by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceuticals” companies are held by institutional investors. 0.8% of Galena Biopharma shares are held by insiders. Comparatively, 11.9% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This is a summary of current ratings for Galena Biopharma and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Galena Biopharma Competitors||830||3722||6747||183||2.55|
Galena Biopharma presently has a consensus target price of $4.00, indicating a potential upside of 995.89%. As a group, “Pharmaceuticals” companies have a potential upside of 24.97%. Given Galena Biopharma’s higher possible upside, equities analysts clearly believe Galena Biopharma is more favorable than its competitors.
Valuation and Earnings
This table compares Galena Biopharma and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Galena Biopharma||N/A||-$23.48 million||-0.21|
|Galena Biopharma Competitors||$8.20 billion||$2.68 billion||-0.95|
Galena Biopharma’s competitors have higher revenue and earnings than Galena Biopharma. Galena Biopharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Galena Biopharma and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Galena Biopharma Competitors||-2,720.56%||-66.58%||-8.79%|
Volatility & Risk
Galena Biopharma has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Galena Biopharma’s competitors have a beta of 0.89, indicating that their average stock price is 11% less volatile than the S&P 500.
Galena Biopharma competitors beat Galena Biopharma on 9 of the 12 factors compared.
Galena Biopharma Company Profile
Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells.
Receive News & Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.